Cytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1408-1421

  Quan, Lei ^a   Gong, Zhihong ^a   Yao, Song ^a   Bandera, Elisa V ^b   Zirpoli, Gary ^a   Hwang, Helena ^a   Roberts, Michelle ^a   Ciupak, Gregory ^a   Davis, Warren ^a   Sucheston, Lara ^a   Pawlish, Karen ^c   Bovbjerg, Dana H ^d   Jandorf, Lina ^e   Cabasag, Citadel ^a   Coignet, Jean Gabriel ^a   Ambrosone, Christine B ^a   Hong, Chi Chen ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

adaptive immune response; African American; breast cancer; cytokine; disparity; estrogen receptor

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; ESTROGEN RECEPTOR; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR; LYMPHOTOXIN; TRANSFORMING GROWTH FACTOR BETA1;

ADAPTIVE IMMUNITY; ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; EUROPEAN AMERICAN; FEMALE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; IFNGR2 GENE; IL15 GENE; IL15RA GENE; IL4R GENE; LTA GENE; MAJOR CLINICAL STUDY; MENOPAUSE; MIDDLE AGED; PRIORITY JOURNAL; RECEPTOR GENE; REGULATORY T LYMPHOCYTE; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; TGFB1 GENE; TH1 CELL; TH2 CELL;

EID: 84891834160     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28458     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Amend K, Hicks D, Ambrosone CB,. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 2006; 66: 8327-30.
3. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005; 97: 439-48.
4. Fregene A, Newman LA,. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer 2005; 103: 1540-50.
5. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009; 27: 4515-21.
6. Hong CC, Yao S, McCann SE, Dolnick RY, Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, Edge SB, Ambrosone CB. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Research and Treatment 2013; 139: 477-88.
7. DeNardo DG, Coussens LM,. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9: 212.
8. Allavena P, Sica A, Garlanda C, et al. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008; 222: 155-61.
9. Kwiatkowski DP,. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Hum Genet 2005; 77: 171-92.
10. Rook GA,. Review series on helminths, immune modulation and the hygiene hypothesis: the broader implications of the hygiene hypothesis. Immunology 2009; 126: 3-11.
11. Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88: 1721-6.
12. DeMichele A, Martin AM, Mick R, et al. Interleukin-6 -174G - >C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63: 8051-6.
13. Snoussi K, Strosberg AD, Bouaouina N, et al. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw 2005; 16: 253-60.
14. Lyon DE, McCain NL, Walter J, et al. Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 2008; 57: 51-8.
15. Grimm C, Kantelhardt E, Heinze G, et al. The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study. BMC cancer 2009; 9: 78.
16. Martin AM, Athanasiadis G, Greshock JD, et al. Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes. Hum Hered 2003; 55: 171-8.
17. Ambrosone CB, Ciupak GL, Bandera EV, et al. Conducting molecular epidemiological research in the age of HIPAA: a multi-institutional case-control study of breast cancer in African-American and European-American women. J Oncol 2009; 2009: 871250.
18. Yao S, Zirpoli G, Bovbjerg DH, et al. Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Res 2012; 14: R58.
19. Yu W, Gwinn M, Clyne M, et al. A navigator for human genome epidemiology. Nat Genet 2008; 40: 124-5.
20. Ruiz-Narvaez EA, Rosenberg L, Wise LA, et al. Validation of a small set of ancestral informative markers for control of population admixture in African Americans. Am J Epidemiol 2011; 173: 587-92.
21. Pritchard JK, Stephens M, Rosenberg NA, et al. Association mapping in structured populations. Am J Hum Genet 2000; 67: 170-81.
22. Narum SR,. Beyond Bonferroni: less conservative analyses for conservation genetics. Conserv Genet 2006; 7: 783-87.
23. Peto J, Mack TM,. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26: 411-14.
24. Ghoussaini M, Fletcher O, Michailidou K, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet 2012; 44: 312-18.
25. Pharoah PD, Antoniou A, Bobrow M, et al. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-6.
26. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006; 107: 4101-8.
27. Takei K, Ikeda S, Arai T, et al. Lymphotoxin-alpha polymorphisms and presence of cancer in 1,536 consecutive autopsy cases. BMC Cancer 2008; 8: 235.
28. Balasubramanian SP, Azmy IA, Higham SE, et al. Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 2006; 6: 188.
29. Qiu LX, Yao L, Mao C, et al. TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47817 subjects. Breast Cancer Res Treat 2010; 123: 563-7.
30. Niu W, Qi Y, Gao P, et al. Association of TGFB1 -509 C>T polymorphism with breast cancer: evidence from a meta-analysis involving 23,579 subjects. Breast Cancer Res Treat 2010; 124: 243-9.
31. Chin Y, Janseens J, Vandepitte J, et al. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res 1992; 12: 1463-6.
32. Kohrt HE, Nouri N, Nowels K, et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005; 2: e284.
33. de Visser KE, Eichten A, Coussens LM,. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
34. Parker DC,. T cell-dependent B cell activation. Annu Rev Immunol 1993; 11: 331-60.
35. Tan TT, Coussens LM,. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007; 19: 209-16.
36. Prochazkova J, Fric J, Pokorna K, et al. Distinct regulatory roles of transforming growth factor-beta and interleukin-4 in the development and maintenance of natural and induced CD4+ CD25+ Foxp3+ regulatory T cells. Immunology 2009; 128: e670-e678.
37. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-80.
38. Barreiro LB, Quintana-Murci L,. From evolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet 2010; 11: 17-30.
39. Giri JG, Anderson DM, Kumaki S, et al. IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. J Leukoc Biol 1995; 57: 763-6.
40. Steel JC, Waldmann TA, Morris JC,. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33: 35-41.
41. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 2000; 60: 1111-16.
42. Oldford SA, Robb JD, Codner D, et al. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int Immunol 2006; 18: 1591-602.
43. Gomez JA, Sun W, Gama V, et al. The C-terminus of interferon gamma receptor beta chain (IFNgammaR2) has antiapoptotic activity as a Bax inhibitor. Cancer Biol Ther 2009; 8: 1771-86.
44. Anthony RM, Rutitzky LI, Urban JF, Jr, et al. Protective immune mechanisms in helminth infection. Nat Rev Immunol 2007; 7: 975-87.
45. Hotez PJ, Brindley PJ, Bethony JM, et al. Helminth infections: the great neglected tropical diseases. J Clin Invest 2008; 118: 1311-21.
46. Quinnell RJ,. Genetics of susceptibility to human helminth infection. Int J Parasitol 2003; 33: 1219-31.
47. Sharma A, Khan R, Joshi S, et al. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 2010; 51: 920-7.
48. Satyam A, Singh P, Badjatia N, et al. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol 2011; 29: 58-65.
49. Kawakami K, Kawakami M, Husain SR, et al. Effect of interleukin (IL)-4 cytotoxin on breast tumor growth after in vivo gene transfer of IL-4 receptor alpha chain. Clin Cancer Res 2003; 9: 1826-36.
50. Roberts AB, Wakefield LM,. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA 2003; 100: 8621-3.